Skip to main
LLY

Eli Lilly (LLY) Stock Forecast & Price Target

Eli Lilly (LLY) Analyst Ratings

Based on 17 analyst ratings
Buy
Strong Buy 41%
Buy 41%
Hold 18%
Sell 0%
Strong Sell 0%

Bulls say

Eli Lilly reported a robust second-quarter performance for 2025, surpassing expectations on both revenue and earnings while also raising its full-year guidance, indicating strong operational momentum. Notably, Mounjaro experienced a significant 60% quarter-over-quarter sales growth internationally, propelled by successful launches in key markets like Brazil, Mexico, and India. Additionally, the anticipated introduction of orforglipron presents an attractive new option in the GLP-1 market, suggesting strong future growth potential for Eli Lilly's portfolio in the cardiometabolic segment.

Bears say

Eli Lilly faces significant downside risks that may negatively impact its stock performance, including potential pricing and rebate pressures, disappointing prescription trajectories for its key drug, tirzepatide (Mounjaro), and the possibility that it will fail to demonstrate cardiac benefits in certain patient populations. Additionally, the recent adverse trend in prescriptions for Zepbound is expected to hinder revenue growth in the upcoming quarter, further stressing the company's sales outlook. The competitive landscape, particularly from orforglipron, poses a substantial threat, leading to adjustments in peak sales forecasts and increasing uncertainty around future revenue generation.

Eli Lilly (LLY) has been analyzed by 17 analysts, with a consensus rating of Buy. 41% of analysts recommend a Strong Buy, 41% recommend Buy, 18% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Eli Lilly and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Eli Lilly (LLY) Forecast

Analysts have given Eli Lilly (LLY) a Buy based on their latest research and market trends.

According to 17 analysts, Eli Lilly (LLY) has a Buy consensus rating as of Jan 9, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $1,109.41, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $1,109.41, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Eli Lilly (LLY)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.